MetaVia Inc. (MTVA)

MetaVia Inc. (MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, based in Boston, Massachusetts. The company was formerly known as NeuroBo Pharmaceuticals and has a development relationship with Dong-A ST of South Korea, from which it licensed its lead programs.

Its lead candidate, DA-1726, is a dual agonist of the GLP-1 and glucagon receptors, designed as an oxyntomodulin analog for the treatment of obesity, with the goal of promoting weight loss while increasing energy expenditure. The company is also developing DA-1241, an oral GPR119 agonist being studied for metabolic dysfunction-associated steatohepatitis, a liver disease linked to obesity and type 2 diabetes.